CYD-TDV dengue vaccine : systematic review and meta-analysis of efficacy, immunogenicity and safety

Tools

Godói, Isabella Piassi and Pires Lemos, Livia Lovato and de Araújo, Vânia Eloisa and Bonoto, Braúlio Cesar and Godman, Brian and Guerra Júnior, Augusto Afonso (2017) CYD-TDV dengue vaccine : systematic review and meta-analysis of efficacy, immunogenicity and safety. Journal of Comparative Effectiveness Research. ISSN 2042-6313 (https://doi.org/10.2217/cer-2016-0045)

[thumbnail of Godói-etal-JCER-2016-CYD-TDV-dengue-vaccine-systematic-review]
Preview
 Text. Filename: God_i_etal_JCER_2016_CYD_TDV_dengue_vaccine_systematic_review.pdf
Accepted Author Manuscript
Download (1MB)| Preview

Abstract

INTRODUCTION: Dengue virus (DENV) is a serious global health problem. CYD-TDC (Dengvaxia(®)) was the first vaccine to gain regulatory approval to try and address this problem.  AIM: Summarize all available evidence on the immunogenicity, efficacy and safety of the CYD-TDV dengue vaccine.  METHOD: Meta-analysis and systematic review.  RESULTS: The best and worst immunogenicity results were for DENV4 and DENV1, respectively. Vaccine efficacy of 60% was derived from studies with participants aged 2-16 years old, with DENV4 and DENV2 presenting the best and worst results, respectively. Erythema and swelling were more frequent with CYD-TDV. No differences were detected for systemic adverse events.  CONCLUSION: CYD-TDV showed moderate efficacy in children and adolescents. From the immunogenicity results in adults, we can expect satisfactory efficacy from vaccination in this population.

CORE (COnnecting REpositories)